COMMUNIQUÉS West-GlobeNewswire

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08/07/2026
NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
08/07/2026
ZUG, Switzerland, July 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment Notification of managers' [...]
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
08/07/2026
SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in [...]
Vaxcyte to Participate in Upcoming Investor Conferences
08/07/2026
SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings [...]
BrightSpring Health Services, Inc. to Announce Second Quarter 2026 Financial Results on July 31, 2026
08/07/2026
LOUISVILLE, Ky., July 08, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its second quarter 2026 financial results [...]
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
08/07/2026
IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide a clear and near- [...]
Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases
08/07/2026
CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an [...]
Cascade Prodrug and Uneedle Advance Collaboration to Enable Suprachoroidal Delivery of CPD100 for Wet AMD
08/07/2026
PORTLAND, Ore. and ENSCHEDE, The Netherlands, July 08, 2026 (GLOBE NEWSWIRE) -- Cascade Prodrug Inc. and Uneedle are advancing their collaboration to evaluate CPD100, Cascade’s first-in-class hypoxia-targeted [...]
SRX Global Reports Preliminary Net Asset Value of Approximately $3.07 Per Share and Over $55 Million in Cash and Short-Term Investments(1)
08/07/2026
Approximately $40 million in cash and more than $15 million in short-term investment assets as of June 30, 2026 1 Estimated net asset value of approximately $60 million and no debt outstanding as of June 30, 2026¹ [...]
Sienna Announces Second Quarter 2026 Results Release Date and Conference Call
08/07/2026
MARKHAM, Ontario, July 08, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) announced that it will report its 2026 second quarter results after market close on Tuesday, [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
08/07/2026
Nantes, le 8 juillet 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), une société de [...]
Half-Year Report on Liquidity Contract with Invest Securities
08/07/2026
NANTES, France, July 8, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) – Under the liquidity contract entrusted by OSE Immunotherapeutics to Invest Securities, the following resources [...]
Bilan semestriel du contrat de liquidité avec Invest Securities
08/07/2026
NANTES, France, le 8 juillet 2026, 18h00 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) – Au titre du contrat de liquidité confié par OSE Immunotherapeutics à Invest Securities, les moyens suivants [...]
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
08/07/2026
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 08 juillet 2026 – GENFIT (Euronext : GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies [...]
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
08/07/2026
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life- [...]
Une première mondiale : le protocole de traitement par cellules souches en une seule séance du KFSH de Djeddah établit une nouvelle référence en matière de sécurité des donneurs et d’efficacité thérapeutique
08/07/2026
DJEDDAH, Royaume d’Arabie saoudite, 08 juill. 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre de Djeddah a développé et mis en œuvre avec succès le premier protocole de ce type au monde [...]
Cerene® Cryotherapy Announces Know Your Flow Event Series To Empower Women Through Free Menstrual and Perimenopause Education
08/07/2026
The First Two Events Will Take Place in New York and Charlotte BERKELEY, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Channel Medsystems’ Cerene® Cryotherapy is proud to announce the launch of its Know Your Flow Event [...]
As America Celebrates its 250th Birthday, Becoming Independent Marks 59 Years of Helping People Live on Their Own Terms
08/07/2026
Becoming Independent Named No. 17 on “The NonProfit Times' 2026 Best Nonprofits To Work For” SANTA ROSA, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Becoming Independent , the North Bay's leading nonprofit serving adults [...]
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
08/07/2026
90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient [...]

Pages